公开(公告)号：US08961976B2

公开(公告)日：2015-02-24

申请号：US14134753

申请日：2013-12-19

Applicant: Biogen Idec Ma Inc.

Inventor： Herman Van Vlijmen ,  Alexey Lugovskoy ,  Karl Hanf

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S435/81

Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.

Abstract translation: 本发明提供了肽及其片段，以及包含其的抗体或其片段，其中与野生型5c8抗体相比，该肽包含至少一个氨基酸取代。 本发明还提供了治疗受试者中CD154相关疾病或病症的组合物和方法。

公开(公告)号：US20150050271A1

公开(公告)日：2015-02-19

申请号：US14386262

申请日：2013-03-15

Applicant: Biogen Idec MA Inc.

Inventor： Kenneth Simon ,  Thomas Cameron ,  Deping Wang ,  Joseph Arndt ,  Mia Rushe ,  Justin Caravella ,  Eric Day

IPC: C07K16/08

CPC classification number: C07K16/084 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.

Abstract translation: 一方面，本公开提供了针对JCV的中和抗体和用于治疗PML的方法。 在一些实施方案中，本发明的方面涉及针对JCV衣壳蛋白VPI（JCV-VP1）的分离的JC-vim中和单克隆抗体。 在一些实施方案中，抗体抑制JC-vims的感染性。 在一些实施方案中，抗体结合JCV-VP1的唾液酸结合口袋。

公开(公告)号：US20140323570A1

公开(公告)日：2014-10-30

申请号：US14264653

申请日：2014-04-29

Applicant: Biogen Idec MA Inc.

Inventor： Ralf GOLD

IPC: A61K31/225

CPC classification number: A61K31/225

Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.

Abstract translation: 提供治疗以广泛脱髓鞘和/或轴突损失为特征的神经障碍的方法。 这种病症的实例包括继发性进行性多发性硬化症和Devic氏病。 所公开的方法包括向具有这种病症的受试者施用治疗有效量的例如富马酸二甲酯或富马酸单甲酯。

公开(公告)号：US20140178382A1

公开(公告)日：2014-06-26

申请号：US13863574

申请日：2013-04-16

Applicant: Biogen IDEC MA, Inc.

Inventor： ANTONIN R. DE FOUGEROLLES ,  VICTOR E. KOTELIANSKI ,  CARL REID ,  ELLEN GARBER

IPC: C07K16/24

CPC classification number: C07K16/24 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.

Abstract translation: 本发明提供结合多种化学试剂，特别是单核细胞趋化蛋白MCP-1，MCP-2和MCP-3的抗体。 本发明还提供产生抗体的细胞，以及制备和使用该抗体的方法。

公开(公告)号：USRE44962E1

公开(公告)日：2014-06-24

申请号：US14017108

申请日：2013-09-03

Applicant: Bayer Cropscience N.V. ,  Biogen Idec MA, Inc.

Inventor： Jan Leemans ,  Johan Botterman ,  Marc De Block ,  Charles Thompson ,  Rao Mouva

IPC: C12N15/52 ,  C12N15/31

CPC classification number: A01H1/00 ,  C07K2319/00 ,  C12N9/1029 ,  C12N15/63 ,  C12N15/70 ,  C12N15/76 ,  C12N15/8277 ,  Y10S47/01

Abstract: The invention relates to a DNA fragment containing a determined gene, the expression of which inhibits the antibiotic and herbicidal effects of Bialaphos and related products.It also relates to recombinant vectors, containing such DNA fragment, which enable this protective gene to be introduced and expressed into cells and plant cells.

Abstract translation: 本发明涉及一种含有确定基因的DNA片段，其表达抑制了Bialaphos及相关产品的抗生素和除草效果。 它还涉及含有这种DNA片段的重组载体，其使得能够将该保护性基因导入细胞和植物细胞中。

公开(公告)号：US20130336991A1

公开(公告)日：2013-12-19

申请号：US13841351

申请日：2013-03-15

Applicant: Biogen Idec MA Inc.

Inventor： Sha MI ,  R. Blake PEPINSKY ,  Zhaohui SHAO ,  Christilyn GRAFF

IPC: C07K16/28

CPC classification number: A61K47/48538 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1138 ,  C12N2310/111 ,  C12N2310/14

Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody

Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成（负调节因子）的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明进一步提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，包括向需要这种治疗的脊椎动物施用有效量的抗Sp35抗体

公开(公告)号：US09676849B2

公开(公告)日：2017-06-13

申请号：US14370828

申请日：2013-01-10

Applicant: Biogen Idec MA Inc.

Inventor： Graham K. Farrington ,  William Sisk

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/46 ,  C07K14/415 ,  C07K14/47

CPC classification number: C07K16/28 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/415 ,  C07K14/4702 ,  C07K16/46 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/33

Abstract: The invention is based, at least in part, on the finding that a dimeric version of a BBB-transmigrating antibody (e.g., the TMEM30A (CDC-50A) binding antibody, FC5) was found to greatly enhance transport across the BBB as compared to monovalent FC5 VHH. The invention provides, inter alia, molecules that increase transport of pharmacologically active agents across the blood brain barrier, methods for increasing transport across the blood brain barrier, and methods of treatment of disorders or diseases having a neurological component.

公开(公告)号：US20160355568A1

公开(公告)日：2016-12-08

申请号：US14379196

申请日：2013-02-15

Applicant: BIOGEN IDEC MA INC.

Inventor： John KULMAN

IPC: C07K14/755 ,  C07K14/435 ,  C07K14/79 ,  C07K14/59 ,  C07K14/705 ,  C07K14/00 ,  C07K14/76

CPC classification number: C07K14/755 ,  A61K35/14 ,  A61K38/00 ,  A61K38/37 ,  C07K14/00 ,  C07K14/43504 ,  C07K14/59 ,  C07K14/705 ,  C07K14/76 ,  C07K14/79 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/60 ,  Y02A50/465 ,  Y02A50/467

Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.

Abstract translation: 提供重组因子VIII蛋白，例如具有插入到因子VIIIA结构域中的柔性允许循环中的异源部分的人因子VIII蛋白质，同时保留因子VIII的促凝血活性。

公开(公告)号：US09353087B2

公开(公告)日：2016-05-31

申请号：US14406081

申请日：2013-06-07

Applicant: Biogen Idec MA Inc. ,  Sunesis Pharmaceuticals, Inc.

Inventor： Brian T. Hopkins ,  Xiongwei Cai ,  Timothy R. Chan ,  Patrick Conlon ,  Michael Humora ,  Tracy J. Jenkins ,  Michael J. Macphee ,  Xianglin Shi ,  Ross A. Miller ,  Andrew Thompson

IPC: A61K31/506 ,  C07D401/14

CPC classification number: C07D401/14 ,  C07B2200/13 ,  C07D207/16 ,  C07D207/28 ,  C07D211/56 ,  C07D401/04

Abstract: The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.

Abstract translation: 本发明提供了一种化合物，固体形式及其组合物，其可用作Bruton酪氨酸激酶的抑制剂，并且其表现出对其的期望特性。 本发明还提供了制备所提供的化合物和固体形式的方法。

公开(公告)号：US09249146B2

公开(公告)日：2016-02-02

申请号：US14316710

申请日：2014-06-26

Applicant: Biogen Idec MA Inc. ,  Sunesis Pharmaceuticals, Inc.

Inventor： Minna Bui ,  Patrick Conlon ,  Julio H. Cuervo ,  Daniel A. Erlanson ,  Junfa Fan ,  Bing Guan ,  Brian T. Hopkins ,  Tracy J. Jenkins ,  Gnanasambandam Kumaravel ,  Alexey A. Lugovskoy ,  Doug Marcotte ,  Noel Powell ,  Daniel Scott ,  Laura Silvian ,  Art Taveras ,  Deping Wang ,  Min Zhong

IPC: C07D401/04 ,  A61K31/519 ,  C07D487/04 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D473/34

CPC classification number: C07D487/14 ,  A61K31/519 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract translation: 本发明提供了可用作Btk抑制剂的化合物，其组合物及其使用方法。